|
市場調查報告書
胰島素抗性診斷能如何拓展胰島素感作物質市場呢？
How Insulin Resistance Diagnostics Can Expand the Market for Insulin-Sensitizing Agents
|
本報告已在2011年12月21日停止出版。
本報告書內容包括：胰島素抗性概要及潛在需求、流行病學、現在的胰島素抗性診斷動向、新的診斷藥及主要企業、未來預測等。內容綱要摘記如下：
實施概要
胰島素抗性試驗的潛在需求
胰島素抗性概要
目前針對胰島素抗性的診斷藥
- Euglycemic Hyperinsulinemic Clamp
- 血漿葡萄糖平均值
- 抽樣血漿葡萄糖
- 空腹時血漿葡萄糖
- 口服葡萄糖負荷測試
- 經常取樣靜脈葡萄糖負荷試驗
- 糖化血紅素A1c
- 空腹時的胰島素測量
- 血液評價模式
針對胰島素抗性的新診斷技術
- KineMed
- Isotechnika
- Syn X
- LipScience
- Entelos
未來預測
附錄A
附錄B
Abstract
Introduction
Insulin resistance is a highly prevalent metabolic condition fraught with
unmet need. Although several diagnostics are in use, not one is ideal; a
standardized, simple tool for measuring IR in clinical practice is needed.
Novel technologies have the potential to create widespread testing for IR in
clinical settings, which would enable early diagnosis and treatment of
prediabetic patients.
Get the Answers You Need to Shape Your Strategy
- Insulin resistance has been tied to many other conditions, including
diabetes, heart attacks, and dyslipidemia. What are the benefi ts of early
insulin resistance diagnosis?
- Several IR tests are used in experimental settings but not widely in
clinical practice. What are the shortcomings of the current tests and what
are clinicians looking for in an IR test?
- Several indexes and tests are used to measure IR, and there is no standard
test used in clinical practice. What are the most common diagnostics used?
Which companies are working toward creating new diagnostics?
- Diagnostic tests that enable earlier detection and therapeutic
intervention for IR may help to delay or prevent the onset of type 2 diabetes
and other diseases. What is the outlook for the current and novel IR
diagnostics and what is their commercial potential?
Scope
- Overview and unmet needs of insulin resistance: defi nition of IR
and metabolic syndrome; unmet need in IR testing; link between IR and other
diseases.
- Epidemiology of insulin resistance: prevalence estimates of IR in
the United States and Europe.
- Current IR diagnostics: Euglycemic hyperinsulinemic clamp,
steady-state plasma glucose, fasting plasma glucose, oral glucose tolerance
test, and others.
- New diagnostics and key players: KineMed' s KineMarkers,
Isotechnika' s Diatest, LipoScience' s NMR LipoProfi le, Entelos' s Metabolism
PhysioLab.
- Outlook and commercial potential: prospects of current and future
diagnostic techniques meeting the unmet need of IR testing.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Unmet Need in Insulin Resistance Testing
- An Overview of Insulin Resistance
- Link Between Insulin Resistance and Other Diseases
- Epidemiology of Insulin Resistance
- Current Diagnostics for Insulin Resistance
- Euglycemic Hyperinsulinemic Clamp
- Steady-State Plasma Glucose
- Random Plasma Glucose
- Fasting Plasma Glucose
- Oral Glucose Tolerance Test
- Frequently Sampled Intravenous Glucose Tolerance Test
- Glycosylated Hemoglobin A1c
- Fasting Insulin Measurements
- Homeostasis Assessment Model
- New Diagnostic Techniques for Insulin Resistance
- KineMed
- Isotechnika
- Syn X
- LipoScience
- Entelos
- Outlook
- Appendix A. Etiology and Pathophysiology of Insulin Resistance
- Appendix B. Bibliography
Tables
- 1. Studies Demonstrating the Relationship Between Insulin Resistance,
Diabetes, and Cardiovascular Diseases
- 2. Updated NCEP-ATP III Criteria for Metabolic Syndrome from the AHA and
NHLBI
- 3. Prevalence of Insulin Resistance in Various Populations
- 4. Number of Total Prevalent Cases of Insulin Resistance Segmented by Type
2 Diabetic and Nondiabetic Subpopulations in the United States and Major
European Markets, 2006-2016
- 5. Indexes Currently Used to Assess Insulin Resistance
- 6. Select Novel Tests and Indexes for Insulin Resistance
- 7. Select Companies with Diagnostics for Insulin Sensitivity/Resistance
- 8. Clinical Trials for the Pharmacological Prevention of Type 2 Diabetes
- A-1. Risk Factors for Insulin Resistance
Figures
- A-1. Clinical Progression of Insulin Resistance
|
